Overview of completed/ongoing phase 3 clinical trials involving rivaroxaban
| . | Comparator . | No. (approximate) of patients . | Results expected/published . | Acronym . |
|---|---|---|---|---|
| AF | VKA | 14 000 | 2010 | ROCKET-AF |
| VTE primary prophylaxis | ||||
| Orthopedic | LMWH | 8 500 | 2008, 200912-15 | RECORD 1-4 |
| Medical | LMWH | 8 000 | 2011 | MAGELLAN |
| VTE acute treatment | LMWH + VKA | 6 200 | 2010 | EINSTEIN DVT and EINSTEIN PE |
| VTE secondary prevention | Placebo (before randomization, all patients received 6-12 months of anticoagulation) | 1 300 | 2010 | EINSTEIN extension study |
| Post–acute coronary syndrome | Placebo (all patients will receive standard treatment, such as aspirin, β-blocker) | 16 000 | Unknown | ATLAS ACS TIMI 51 |
| . | Comparator . | No. (approximate) of patients . | Results expected/published . | Acronym . |
|---|---|---|---|---|
| AF | VKA | 14 000 | 2010 | ROCKET-AF |
| VTE primary prophylaxis | ||||
| Orthopedic | LMWH | 8 500 | 2008, 200912-15 | RECORD 1-4 |
| Medical | LMWH | 8 000 | 2011 | MAGELLAN |
| VTE acute treatment | LMWH + VKA | 6 200 | 2010 | EINSTEIN DVT and EINSTEIN PE |
| VTE secondary prevention | Placebo (before randomization, all patients received 6-12 months of anticoagulation) | 1 300 | 2010 | EINSTEIN extension study |
| Post–acute coronary syndrome | Placebo (all patients will receive standard treatment, such as aspirin, β-blocker) | 16 000 | Unknown | ATLAS ACS TIMI 51 |